US Patent 11866414 Substituted heterocyclic compounds
Patent 11866414 was granted and assigned to Bristol-Myers Squibb Company on January, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 23 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 25 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+18 properties)
US Patent 11866414 Substituted heterocyclic compounds
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Michael Edward Mertzman0
Ryan M. Moslin0
Steven H. Spergel0
Zili Xiao0
Date of Patent
January 9, 2024
0Patent Application Number
177435570
Date Filed
May 13, 2022
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11866414 Substituted heterocyclic compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.